CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab

BACKGROUND: Immune-check point inhibitors (ICPIs) for treatment of cancer patients sometimes induce potentially life-threatening immune-related adverse events (irAEs), which predict ICPIs treatment efficacy. Prediction of irAEs would be useful for management of irAEs and prediction of ICPIs efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsunaga, Tomoyuki, Saito, Hiroaki, Kuroda, Hirohiko, Osaki, Tomohiro, Takahashi, Sadamu, Iwamoto, Akemi, Fukumoto, Yoji, Taniguchi, Kenjiro, Fukuda, Kenji, Miyauchi, Wataru, Shishido, Yuji, Miyatani, Kozo, Fujiwara, Yoshiyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013067/
https://www.ncbi.nlm.nih.gov/pubmed/35428212
http://dx.doi.org/10.1186/s12885-022-09482-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013067/
https://www.ncbi.nlm.nih.gov/pubmed/35428212
http://dx.doi.org/10.1186/s12885-022-09482-8

Ejemplares similares